Literature DB >> 16190907

Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease.

Eugenia Papalexi1, Anna Persson, Maria Björkqvist, Asa Petersén, Ben Woodman, Gillian P Bates, Frank Sundler, Hindrik Mulder, Patrik Brundin, Natalija Popovic.   

Abstract

Reductions in testosterone and luteinizing hormone levels and reduced sexual functions have been reported in Huntington's disease (HD) patients. Atrophy of the reproductive organs and loss of fertility have also been observed in the R6/2 mouse, which is currently the most studied transgenic model of HD. In an effort to define the cause of infertility we studied the expression of gonadotropin-releasing hormone (GnRH) in the medial septum, diagonal band of Broca and hypothalamus of R6/2 male mice during sexual maturation. We found a progressive reduction in the numbers of GnRH-immunoreactive neurons in the analysed brain areas of R6/2 mice starting at 5 weeks of age and becoming statistically significant with only 10% of the neurons remaining by 9 weeks of age. Atrophy of testes and seminal vesicles combined with a significant reduction in serum and testicular testosterone levels were detected in 12-week-old R6/2mice. These results suggest that infertility in the R6/2 males is due either to death of GnRH neurons or to a reduction in GnRH expression leading to a downstream impairment of the gonadotropic hormones. Gonadotropic hormone replacement did not mitigate weight loss or restore motor function in R6/2 males.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16190907     DOI: 10.1111/j.1460-9568.2005.04324.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  21 in total

Review 1.  Sexuality in Huntington's disease.

Authors:  Eva Z Schmidt; Raphael M Bonelli
Journal:  Wien Med Wochenschr       Date:  2008

Review 2.  Choosing an animal model for the study of Huntington's disease.

Authors:  Mahmoud A Pouladi; A Jennifer Morton; Michael R Hayden
Journal:  Nat Rev Neurosci       Date:  2013-10       Impact factor: 34.870

Review 3.  Fibroblast growth factor signaling in the developing neuroendocrine hypothalamus.

Authors:  Pei-San Tsai; Leah R Brooks; Johanna R Rochester; Scott I Kavanaugh; Wilson C J Chung
Journal:  Front Neuroendocrinol       Date:  2010-12-01       Impact factor: 8.606

4.  Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy.

Authors:  Bronwen Martin; Wayne Chadwick; Wei-na Cong; Nick Pantaleo; Caitlin M Daimon; Erin J Golden; Kevin G Becker; William H Wood; Olga D Carlson; Josephine M Egan; Stuart Maudsley
Journal:  J Biol Chem       Date:  2012-07-20       Impact factor: 5.157

Review 5.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

6.  An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes.

Authors:  Amber L Southwell; Amy Smith-Dijak; Chris Kay; Marja Sepers; Erika B Villanueva; Matthew P Parsons; Yuanyun Xie; Lisa Anderson; Boguslaw Felczak; Sabine Waltl; Seunghyun Ko; Daphne Cheung; Louisa Dal Cengio; Ramy Slama; Eugenia Petoukhov; Lynn A Raymond; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2016-07-04       Impact factor: 6.150

7.  Localization of neuroglobin in the brain of R6/2 mouse model of Huntington's disease.

Authors:  A Cardinale; F R Fusco; E Paldino; C Giampà; M Marino; M T Nuzzo; V D'Angelo; D Laurenti; G Straccia; D Fasano; D Sarnataro; T Squillaro; S Paladino; Mariarosa A B Melone
Journal:  Neurol Sci       Date:  2017-11-03       Impact factor: 3.307

8.  Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.

Authors:  Brett D Dufour; Jodi L McBride
Journal:  Neurobiol Dis       Date:  2018-10-05       Impact factor: 5.996

9.  Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.

Authors:  Hilary Moffitt; Graham D McPhail; Ben Woodman; Carl Hobbs; Gillian P Bates
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

10.  Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease.

Authors:  Chiara Zuccato; Nikolai Belyaev; Paola Conforti; Lezanne Ooi; Marzia Tartari; Evangelia Papadimou; Marcy MacDonald; Elisa Fossale; Scott Zeitlin; Noel Buckley; Elena Cattaneo
Journal:  J Neurosci       Date:  2007-06-27       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.